Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (96)

I-01Noha Abdelgawad

Population pharmacokinetic modeling of rifampicin at standard and high doses in adults with tuberculous meningitis

Wednesday 10:00-11:30

I-02Chayan Acharya

Population PK analysis of Pegaspargase in Japanese and non-Japanese patients with acute lymphoblastic leukemia

Wednesday 10:00-11:30

I-05Bram Agema

Development of covariate-informed model pooling method to predict the correct starting dose

Wednesday 10:00-11:30

I-06Ana Alarcia Lacalle

Population pharmacokinetic modelling and Monte Carlo simulation of piperacillin administered as extended infusion in critically ill patients

Wednesday 10:00-11:30

I-07Mounier Almett

Population Pharmacokinetic Modelling of Twice Daily 50mg Dolutegravir in Children with Tuberculosis and HIV during Rifampicin Co-administration

Wednesday 10:00-11:30

I-08Stephen Amori

apmx: an open-source R package for automated PK and PKPD dataset assembly

Wednesday 10:00-11:30

I-09Lena Appel

Comparing the objective function value in NONMEM is valid for model selection when fixing THETA or OMEGA but not when fixing ETAs

Wednesday 10:00-11:30

I-10Arkadiusz Adamiszak

Antibiotic pharmacokinetic modelling versus antibiotic therapy optimisation and resistance reduction: Bibliometric analysis

Wednesday 10:00-11:30

I-11Marcus Baaz

Model-based Prediction of Progression-Free Survival for Combination Therapies in Oncology

Wednesday 10:00-11:30

I-12Annabelle Ballesta

Quantitative Systems Pharmacology to Personalize Temozolomide-based Drug Combinations against Brain Tumors.

Wednesday 10:00-11:30

I-13Aurélie Barrail-Tran

Population pharmacokinetic modelling of dolutegravir, tenofovir and emtricitabine in non-human primates

Wednesday 10:00-11:30

I-14Imke Bartelink

Physiologically based pharmacokinetic modelling of the PSMA radioligand 18F-DCFPyL to predict the tissue distribution in patients with prostate cancer

Wednesday 10:00-11:30

I-15Carla Bastida Fernández

Tigecycline population pharmacokinetics in critically ill patients with decompensated cirrhosis and severe infections

Wednesday 10:00-11:30

I-16Maxime Beaulieu

Simulation study to evaluate the identifiability of a non-linear multi-level joint model for the follow-up of patients with cancer

Wednesday 10:00-11:30

I-17Dinesh Bharadwaj Bedathuru

Comparing Multiple Virtual Population Generation Approaches using as a base, a QSP Model of Rheumatoid Arthritis.

Wednesday 10:00-11:30

I-18Laura Ben Olivo

Model-informed precision dosing web tool of busulfan for Brazilian pediatric patients

Wednesday 10:00-11:30

I-19Sandra Berja

Population PK analysis of chloroquine in a humanized mouse model of P.falciparum malaria

Wednesday 10:00-11:30

I-20Elisa Borella

Elacestrant Population Pharmacokinetic and Exposure-Response Modelling Analyses to Support Elacestrant Dose Recommendations in Metastatic Breast Cancer (mBC) patients

Wednesday 10:00-11:30

I-21Muriel Boulton

Exposure-Response (E-R) analysis of efficacy and safety of niraparib/abiraterone acetate combination in patients with metastatic castration-resistant prostate cancer

Wednesday 10:00-11:30

I-22Jose Miguel Calderin Miranda

Pharmacokinetic analysis of pyrazinamide in a South African population with tuberculosis meningitis and HIV

Wednesday 10:00-11:30

I-23Aurore CARROT

Prognostic value of the modeled CA-125 kinetics parameter KELIM-PARP in patients with advanced ovarian cancer (AOC): analysis of the phase II BOLD study

Wednesday 10:00-11:30

I-24Marc Cerou

Semi mechanistic joint modeling of tumor dynamics and PFS in advanced breast cancer: leveraging data from early amcenestrant phase I-II trials

Wednesday 10:00-11:30

I-25Anan Chanruang

Population pharmacokinetics of dolutegravir co-administered with rifampicin in Thai people living with HIV and TB

Wednesday 10:00-11:30

I-26Zhendong Chen

Plasma and cerebrospinal fluid population pharmacokinetics of vancomycin in patients with external ventricular drain

Wednesday 10:00-11:30

I-27Mohammed Cherkaoui Rbati

The transit compartment model: The truth behind n!

Wednesday 10:00-11:30

I-28Siak-Leng CHOI

Applying a quantitative system pharmacology (QSP) model to inform KRASG12C covalent inhibitors’ PK driver level needed for efficacy in patients with non-small cell lung cancer (NSCLC)

Wednesday 10:00-11:30

I-29John Clements

Model-Based Meta-Analysis in Newly Diagnosed and Relapsed Refractory Multiple Myeloma to Support Outcome-Efficacy Translations and Extrapolations Across Lines of Therapy

Wednesday 10:00-11:30

I-30Francois Combes

Benchmarking Industrial Computing Environments – Pharmacometrics Study (BICEPS)

Wednesday 10:00-11:30

I-31Eulalie Courcelles

Generation of a virtual population for a multi-strain model of natural and vaccinal immunization against influenza

Wednesday 10:00-11:30

I-32Ivan Demin

Population pharmacokinetics of LXE408 in healthy volunteers and dose predictions for adults and pediatric patients with visceral leishmaniasis

Wednesday 10:00-11:30

I-33Anthea Deschamps

Pharmacokinetics of cefotaxime in intensive care patients: exploration of the sources of variability with a population model

Wednesday 10:00-11:30

I-34Thomas Duflot

Modelling of plasma unbound Ceftriaxone: can we improve efficacy in clinical practice ?

Wednesday 10:00-11:30

I-35Zrinka Duvnjak

Performance evaluation of the full Automatic Model Development (AMD) tool when the true model is known

Wednesday 10:00-11:30

I-36Kevin Dykstra

Population pharmacokinetics of vadadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor for treatment of anemia associated with chronic kidney disease

Wednesday 10:00-11:30

I-37Omar Elkayal

Model-based dose optimisation of intravenous posaconazole for treatment of patients with invasive aspergillosis in the intensive care unit

Wednesday 10:00-11:30

I-38Xiaoqing Fan

Pharmacokinetic and pharmacodynamic modeling of erythropoietin and romiplostim combination therapy in rats with chemotherapy-induced anemia and thrombocytopenia

Wednesday 10:00-11:30

I-39Aneeq Farooq

In vitro pharmacokinetic/pharmacodynamic interaction model assessing the synergy between meropenem and fosfomycin in a clinical multi-resistant K. pneumoniae isolate.

Wednesday 10:00-11:30

I-40Fernandez Teruel Carlos

Exposure–response analysis of safety and efficacy of capivasertib administered as monotherapy or in combination with fulvestrant

Wednesday 10:00-11:30

I-41Matthew Fidler

nlmixr2, rxode2 and NONMEM: interchangeable models using babelmixr2 and nonmem2rx

Wednesday 10:00-11:30

I-42Nuria Folguera-Blasco

Studying Targeted Protein Degradation Using a Quantitative Systems Pharmacology (QSP) Approach for Proteolysis Targeting Chimeras (PROTACs)

Wednesday 10:00-11:30

I-43Wei Gao

Population PK/PD modeling of blood- and liver-stage activities of cabamiquine in malaria

Wednesday 10:00-11:30

I-44Glenn Gauderat

Mechanistic modelling of tumor uptake & interstitial receptor occupancy of PRS-344/S095012 using preclinical positron emission tomography data

Wednesday 10:00-11:30

I-45Kamunkhwala Gausi

Bactericidal activity of pretomanid against drug-sensitive tuberculosis in the presence of rifamycins

Wednesday 10:00-11:30

I-46Eva Germovsek

A semi-mechanistic model to describe preclinical tumour viral dynamics of an oncolytic virus

Wednesday 10:00-11:30

I-47Asina Gijasi

Development of an R Shiny application to aid pre-clinical development of immune-oncology compounds at Genmab

Wednesday 10:00-11:30

I-48Daniel Glazar

A simulation-based sample size analysis of a joint model of longitudinal and survival data for patients with glioma

Wednesday 10:00-11:30

I-49Xiaohua Gong

Pharmacometric Analysis in Support of Dose Optimization for Pemigatinib Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangements

Wednesday 10:00-11:30

I-50Sebastiaan Goulooze

Conditional overall survival (OS) simulations with a joint tumor size (TS)-OS model to support oncology development decision making

Wednesday 10:00-11:30

I-51Mélanie Guhl

Uncertainty computation at finite distance in nonlinear mixed effects models – a new method evaluated on simulations and applied to the evolution of clinical status of patients hospitalised for COVID-19

Wednesday 10:00-11:30

I-52Jinju Guk

Integration of early circulating tumour DNA (ctDNA) changes into tumour growth inhibition modelling.

Wednesday 10:00-11:30

I-53Michael Hackl

Visualising and integrating automated model development within a validated environment

Wednesday 10:00-11:30

I-54Ibtihel Hammami

Application of Physiologically Based Pharmacokinetic Model to Predict Cobicistat Concentration during Pregnancy

Wednesday 10:00-11:30

I-55Irene Hernández-Lozano

Translational pharmacokinetic-pharmacodynamic (PKPD) modelling of apramycin to facilitate prediction of efficacious dose in urinary tract infections

Wednesday 10:00-11:30

I-56Jennifer Hibma

Population Pharmacokinetic Analysis of Elranatamab in Patients with Multiple Myeloma

Wednesday 10:00-11:30

I-57Nick Holford

A Physiological Approach to Renal Clearance – from Premature Neonates to Adults

Wednesday 10:00-11:30

I-58Miao-Chan Huang

Population pharmacokinetic analysis of amoxicillin in postpartum Göttingen Minipig plasma and milk: a contribution from the ConcePTION project

Wednesday 10:00-11:30

I-59Itziar Irurzun Arana

Population PK modelling of camizestrant, a next-generation oral selective estrogen receptor degrader, as monotherapy and in combination with palbociclib in ER+/HER2- advanced breast cancer

Wednesday 10:00-11:30

I-60Hyeseon Jeon

Construction of model-based PK-PD software platform using R package considering compatibility of nlme structured model

Wednesday 10:00-11:30

I-61Jihyun Jeon

Quantitative approaches of time-varying weight gain effects of antipsychotic drugs for Schizophrenia by model based meta-analysis.

Wednesday 10:00-11:30

I-62Felix Jost

Model-based analysis of the treatment window in passive cutaneous anaphylaxis mouse model applying an optimized study design

Wednesday 10:00-11:30

I-63Piotr Juszczak

Modelling humoral immune response after a single RSV vaccination in RSV-seropositive adults aged 60 and older

Wednesday 10:00-11:30

I-64Allan Kengo

Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin.

Wednesday 10:00-11:30

I-65Charlotte Kern

Oral ivermectin population pharmacokinetics modeling in venous plasma in healthy study participants in Kenya in preparation of BOHEMIA cluster randomized controlled trial

Wednesday 10:00-11:30

I-66Dohoon Keum

Model-based optimal dosing regimen for recombinant hepatitis B human immunoglobulin (GC1102) in Chronic Hepatitis B Patients

Wednesday 10:00-11:30

I-67Huub Jan Kleijn

Population Pharmacokinetic Analysis of PD-L1 Checkpoint Inhibitor Cosibelimab in Subjects with Advanced Cancers

Wednesday 10:00-11:30

I-68Fenja Klima

Separating out multi-analyte endoxifen measurements: Derivation of a conversion factor to enable assessment of analytically heterogeneous clinical trial data

Wednesday 10:00-11:30

I-69Simon Koele

Population pharmacokinetics of sutezolid and its main metabolite to characterize the exposure-response relationship in patients with pulmonary tuberculosis

Wednesday 10:00-11:30

I-70Sjoerd Koopman

Bayesian forecasting of recombinant factor IX-Fc fusion protein concentrate dosing in haemophilia B patients: Comparison of the performance of two population pharmacokinetic models

Wednesday 10:00-11:30

I-71Hongjae Lee

Population pharmacokinetics of FM101 in healthy volunteers and long-term safety prediction: phase 1 study

Wednesday 10:00-11:30

I-72Yu-wei Lin

Population pharmacokinetic analysis of DOVATO (DTG/3TC) as a fixed-dose combination (FDC), in antiretroviral therapy (ART)-naive HIV-1-infected adolescents, ≥12 to <18 years of age who weigh at least 25 kg

Wednesday 10:00-11:30

I-73Ioannis Loisios-Konstantinidis

Combining physiologically based pharmacokinetic modeling and simulations and allometry to inform the starting dose of asciminib in pediatric patients

Wednesday 10:00-11:30

I-74Anaëlle Monfort

A population pharmacokinetic model for sertraline in depressive patients during the perinatal period: prediction of infant drug exposure through placenta and human milk

Wednesday 10:00-11:30

I-75Michael Monine

Prediction and validation of antisense oligonucleotide distribution in human central nervous system

Wednesday 10:00-11:30

I-76Nele Mueller-Plock

Population pharmacokinetic – pharmacodynamic analysis of dopamine D2 receptor occupancy following doses of TV 46000, an extended release suspension of risperidone for treatment of schizophrenia

Wednesday 10:00-11:30

I-77Paraskevi Papakyriakopoulou

Donepezil brain and blood pharmacokinetic modeling after nasal film and oral solution administration in mice

Wednesday 10:00-11:30

I-78Juan Jose Perez Ruixo

Nipocalimab Dose Selection for A Phase 3 Study in Adult Patients with Generalized Myasthenia Gravis

Wednesday 10:00-11:30

I-79Belén Pérez Solans

Pharmacokinetic analysis across studies to drive knowledge-integration: optimal dose finding of rifampicin for the treatment of drug-susceptible tuberculosis in children

Wednesday 10:00-11:30

I-80Soumya Perinparajah

Modelling the pharmacodynamics of rituximab biosimilar in children with rheumatological conditions

Wednesday 10:00-11:30

I-81Anne Ravix

Dosing optimization of amoxicillin in children treated for Lyme disease

Wednesday 10:00-11:30

I-82Leyanis Rodriguez Vera

Showcasing the potential of PBPK modeling to inform drug-drug interactions specific recommendations for pediatric labeling: omeprazol case example

Wednesday 10:00-11:30

I-83Kyong Kuk Ryu

Population pharmacokinetics of ticagrelor and active metabolite during veno-arterial extracorporeal membrane oxygenation

Wednesday 10:00-11:30

I-84Stephan Schaller

Using PBPK Modeling to support an adaptive “First-in-Pediatric” trial design of Sonlicromanol for the treatment of Primary Mitochondrial Disease

Wednesday 10:00-11:30

I-85Maja Skataric

Dabrafenib and Trametinib dose optimization in 6-17 year old tumor agnostic patients based on established efficacy surrogate targets in adults

Wednesday 10:00-11:30

I-86Melina Steichert

Enalapril orodispersible minitablets for pediatric heart failure – a population pharmacokinetic analysis from multicenter Phase II/III LENA clinical trials

Wednesday 10:00-11:30

I-87

Population pharmacokinetic and exposure-response analysis for ambrisentan for the treatment of pulmonary arterial hypertension in paediatric subjects aged 8 to less than 18 years.

Wednesday 10:00-11:30

I-88Elena Tosca

Predicting tumor volume doubling time and progression-free survival curves in cancer patients from patient-derived-xenograft (PDX) models: a translational model-based population approach

Wednesday 10:00-11:30

I-89Mira Tout

A translational minimal physiologically-based pharmacokinetic (mPBPK) model to predict preclinical and clinical PK of MEN1703 in tissues

Wednesday 10:00-11:30

I-90Lufina Tsirizani

Population pharmacokinetics of ritonavir-boosted darunavir in children aged 3 to 15 years in the CHAPAS 4 trial living with HIV in Africa.

Wednesday 10:00-11:30

I-91Lisa van der Heijden

Quantification of the difference in oral docetaxel pharmacokinetics in patients with prostate cancer compared to patients with other solid tumours

Wednesday 10:00-11:30

I-92Sebastian Wicha

In vitro pharmacodynamic drug-drug interaction and translational evaluation of cabamiquine and pyronaridine as new antimalarial combination using P.falciparum field isolates

Wednesday 10:00-11:30

I-93Marie Wijk

Analysis of Mycobacterium tuberculosis time to positivity in response to treatment in South African patients with drug-susceptible tuberculosis

Wednesday 10:00-11:30

I-94Venkata Yellepeddi

Population Pharmacokinetics of Intermittent Vancomycin in Cystic Fibrosis Patients

Wednesday 10:00-11:30

I-95Anyue Yin

Population pharmacokinetics and toxicity analysis of high-dose methotrexate in patients with central nervous system lymphoma

Wednesday 10:00-11:30

I-96Seok Kyue Yoon

Disease progression modeling analysis of the change of bone mineral density by postoperative hormone therapies in postmenopausal patients with early breast cancer

Wednesday 10:00-11:30

I-97Yu-Jou Lin

A pharmacometric multistate model for analyzing long-term outcomes of patients with drug-resistant tuberculosis under bedaquiline treatment

Wednesday 10:00-11:30

I-98Renwei Zhang

A model-based meta-analysis of immune-related adverse events during immune checkpoint inhibitors treatment for NSCLC

Wednesday 10:00-11:30